International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

Treatment and Management of Parkinson Disease

Gaganpreet Singh[1], Dr. Ajeet Pal Singh[2], Parul Verma[3], Kiran Bala[4],Dr. Amar Pal Singh[5]

St.Soldier Institute of Pharmacy, Lidhran Campus, Behind NIT (R.E.C), Jalandhar -Amritsar By Pass Nh-1, Jalandhar 144011, Punjab, India

Date of Submission: 01-04-2025 Date of Acceptance: 10-04-2025

ABSTRACT: Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily affecting motor functions due to the loss of dopamine-producing neurons in the brain. It is characterized by motor symptoms such as tremor, rigidity, bradykinesia, and postural instability, as well as non-motor symptoms like cognitive decline, depression, and sleep disturbances. The etiology of PD remains unclear, with both genetic and environmental factors contributing to its onset. While there is no cure for PD, treatments focus on symptom management and improving the quality of life for affected individuals. Levodopa remains the primary pharmacological treatment, often combined with other agents such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors. Non-pharmacological therapies, including physical, occupational, and speech therapy, play a critical role in maintaining functional independence. In advanced stages, deep brain stimulation (DBS) is utilized to alleviate symptoms in patients who no longer respond to medications. This paper discusses the pathogenesis, treatment modalities, and management strategies for Parkinson's disease, highlighting the importance of both pharmacological and non-pharmacological approaches in improving patient outcomes. Despite significant advancements in treatment, research into disease-modifying therapies continues to be a major focus, with promising avenues exploring neuroprotective strategies and genetic interventions.

Keywords: Parkinsondisease (PD), Bradykinesia,Neurodegeneration, Dopamine, Neuroinflammation, Substantia nigra.

I. INTRODUCTION:

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects motor function due to the loss of dopamine-producing neurons in the brain. First described by Dr. James Parkinson in 1817 in his seminal work "An Essay on the Shaking Palsy," the disease has since become a focal point of research and clinical focus. PD is typically characterized by a combination of motor symptoms such as tremor, rigidity, bradykinesia (slowness of movement), and postural instability. While it primarily affects movement, non-motor symptoms such as cognitive decline, depression, sleep disturbances, and autonomic dysfunction can also significantly impair quality of life . The cause of PD is not fully understood, but it is believed to result from a combination of genetic and environmental factors. Genetic mutations have been identified in several familial forms of the disease, but the vast majority of PD cases are sporadic. Environmental risk factors, such as exposure to pesticides or rural living, may also contribute to the onset of the disease. The degeneration of dopamine-producing neurons, especially in a part of the brain called the substantia nigra, leads to the hallmark motor symptoms of Parkinson's disease .WhilePD is most commonly diagnosed in individuals over the age of 60, early-onset Parkinson's (diagnosed before age 50) also occurs, though it is less common. The incidence of PD is increasing globally, partly due to aging populations, making it a significant public health concern. In the United States alone, it is estimated that over 10 million people live with PD (Dorsey et al., 2018).Current treatments for Parkinson's disease primarily aim to manage symptoms, as no cure exists. Medications such as levodopa and dopamine agonists are used to improve motor function, while deep brain stimulation (DBS) has been shown to be effective for patients with advanced disease. Research into disease-modifying therapies is ongoing, with a focus on neuroprotective strategies and the development of treatments targeting the underlying pathophysiology of PD.

II. PATHOGENESIS:

Parkinson's disease (PD) is a neurodegenerative condition that mostly affects dopaminergic neurons in the substantia nigra. It

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

causes bradykinesia, stiffness, tremor, and postural instability, among other motor symptoms. A number of important pathways contribute to neurodegeneration in the complex pathophysiology of Parkinson's disease (PD), which includes both hereditary and environmental factors:

2.1. Degeneration:Motor dysfunction results from the loss of dopamine-producing neurons in the substantia nigra, which disrupts communication with the striatum. Oxidative stress, excitotoxicity, and mitochondrial dysfunction all worsen the deterioration.

2.2 Alpha-Synuclein Aggregation: The buildup of misfolded alpha-synuclein, which results in Lewy bodies, is a defining feature of Parkinson's disease. This aggregation leads to neuroinflammation, mitochondrial dysfunction, and disruption of cellular processes. It is believed that alpha-synuclein aggregation contributes to the advancement of illness by spreading like a prion.

2.3Mitochondrial Dysfunction: Mitochondria in dopaminergic neurons are vulnerable to damage, leading to impaired ATP production, increased ROS, and oxidative stress, which worsen neuronal injury. Defective mitochondrial quality control, such as impaired mitophagy, also contributes to neurodegeneration.

2.4 Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines, reactive oxygen species, and neurotoxic molecules, exacerbating neuronal damage. Chronic inflammation is a key feature in the progression of PD.

2.5Genetic Factors: Genetic mutations in genes like SNCA (alpha-synuclein), LRRK2 (leucine-rich repeat kinase 2), PARK2 (Parkin), and PINK1 (PTEN-induced kinase 1) have been linked to familial forms of PD. These genes are involved in protein aggregation, mitochondrial function, and cellular homeostasis.

2.6Environmental Factors: A higher risk of Parkinson's disease has been associated with exposure to environmental pollutants, including pesticides. However, some protective effects could be provided by things like coffee use and smoking .



FIG: PATHOGENESIS OF PARKINSON DISEASE

III. PHARMACOLOGICAL TREATMENTS:

3.1LEVODOPA(L-DOPA):

Levodopa is considered the primary treatment for Parkinson's disease. It acts as a precursor to dopamine, capable of crossing the blood-brain barrier and being transformed into dopamine within the brain. Typically, levodopa is administered alongside a peripheral decarboxylase inhibitor, such as carbidopa or benserazide, to inhibit its conversion to dopamine outside the brain, thereby minimizing side effects like nausea.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

3.1.1Common formulation: The common formulation is Sinemet, which combines levodopa andcarbidopa.

3.1.2Mechanism: The mechanism involves L-DOPA being converted into dopamine in the brain, aiding in restoring the depleted dopamine levels in individuals with Parkinson's .

PHARMACOKINETIC:

Levodopa is a key medication in treating Parkinson's disease (PD). Absorption, distribution, metabolism, and elimination are all part of its pharmacokinetics:

- **Absorption**: Within 1-2 hours of oral treatment, levodopa reaches its peak plasma concentrations due to its quick absorption in the small intestine. Food, particularly proteins, might affect its absorption since they vie for the same transport mechanism.
- **Distribution**: Levodopa enters the circulation and uses an active transport mechanism to pass past the blood-brain barrier (BBB). The enzyme aromatic L-amino acid decarboxylase then transforms the medication into dopamine in the brain.
- **Metabolism:** The liver and peripheral tissues outside the brain are where levodopa is mostly broken down by the enzyme's decarboxylase and COMT (catechol-O-methyltransferase). Only a little portion of the medication makes it to the brain, where it works as a medication.
- **Elimination:** Dopamine and its derivatives are the primary metabolites that levodopa is expelled as in the urine.

Levodopa needs several doses per day to maintain therapeutic benefits because of its brief half-life (about one to two hours). Carbidopa is frequently used in conjunction with levodopa to avoid peripheral conversion to dopamine .

3.2 DOPAMINE AGONISTS:

Dopamine agonists replicate the action of dopamine in the brain by directly activating dopamine receptors. They are frequently used alongside levodopa therapy or in the early stages of Parkinson's disease to postpone the necessity for levodopa.
Examples: Pramipexole, Ropinirole, Rotigotine, Apomorphine.

3.2.1Mechanism: These medications attach to dopamine receptors (D2, D3) in the brain and stimulate them, thereby offering symptomatic relief

PHARMACOKINETICS:

- **Absorption:** The gastrointestinal system absorbs dopamine agonists well. Pramipexole and ropinirole, for instance, are usually administered orally and reach their peak plasma concentrations in one to two hours. A transdermal patch called rotigotine offers constant release dopamine stimulation that never stops.
- **Distribution:** The body has a large distribution of these medications. The volume of distribution for pramipexole is around 500 L, although the distribution profile for ropinirole is comparable. They work on the brain's dopamine receptors by overcoming the blood-brain barrier.
- **Metabolism:** Cytochrome P450 enzymes, mainly CYP1A2, metabolize ropinirole in the liver, while pramipexole undergoes little metabolization and is mostly eliminated unaltered in the urine. Rotigotine's hepatic metabolism is restricted.
- **Elimination:** The kidneys are the main organs responsible for the removal of dopamine agonists. The half-life of ropinirole is around 6–8 hours, while that of pramipexole is about 8–12 hours. Due to its patch composition, rotigotine is delivered gradually over a 24-hour period, with a half-life of around 5-7 hours.

3.3 MONOAMINE OXIDASE B (MAO-B) INHIBITORS

MAO-B inhibitors function by elevating dopamine levels through the inhibition of the enzyme monoamine oxidase B, which plays a role in dopamine degradation in the brain.
Examples: Selegiline, Rasagiline.

3.3.1Mechanism: These medications enhance dopaminergic activity by blocking MAO-B, thus preventing dopamine from being broken down.

PHARMACOKINETICS:

- **Absorption:** When taken orally, MAOIs are usually effectively absorbed. The gastrointestinal system absorbs rasagiline and selegiline quickly.
- **Distribution:** By blocking MAO-B in the central nervous system (CNS), these medications produce their therapeutic effects in the brain and other parts of the body.
- **Metabolism:** The liver breaks down selegiline into a number of metabolites, such as amphetamine and methamphetamine, which

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

have stimulant properties. Rasagiline contains fewer active metabolites than selegiline and is mostly metabolized by the CYP1A2 enzyme.

- **Elimination:** A minor quantity of both medications is expelled through stools, while the majority are removed by urine.

3.4 CATECHOL-O-METHYLTRANSFERASE (COMT) INHIBITORS:

COMT inhibitors are employed to extend the duration of levodopa's effects by blocking the COMT enzyme, which is responsible for metabolizing levodopa outside the brain.
Examples: Entacapone, Tolcapone.

3.4.1 Mechanism: These medications inhibit the breakdown of levodopa in the periphery, allowing a greater amount to reach the brain.

PHARMACOKINETICS:

- **Absorption:** The gastrointestinal system absorbs it quickly, and peak plasma concentrations are attained in around one hour.
- **Distribution:** It is widely dispersed throughout the body;however, it operates peripherally and has a poor capacity to pass through the blood-brain barrier.
- **Metabolism:** Conjugation (glucuronidation) is the main method of metabolism in the liver. The CYP450 enzymes do not appreciably metabolize it.
- **Elimination:** 90% of the medication is removed as metabolites in the urine. With a half-life of around one and a half hours, frequent dosage is necessary (typically with each dose of levodopa) .

3.5 ANTICHOLINERGIC AGENTS:

Anticholinergic drugs are employed to alleviate tremors and stiffness associated with Parkinson’s disease. They function by inhibiting the effects of acetylcholine, which is believed to be excessively active in Parkinson’s disease due to diminished dopaminergic activity.
Examples: Itincludes Benztropine and Trihexyphenidyl.

3.5.1.Mechanism: These medications obstruct acetylcholine receptors in the brain, thereby reestablishing the equilibrium between dopamine and acetylcholine .

3.6 AMANTADINE:

It is an antiviral medication that has been shown to have anti-glutamatergic and dopaminergic effects. It is used to manage dyskinesias in particular when treating Parkinson's disease.
Mechanism: Amantadine reduces motor symptoms by increasing dopamine release, blocking its reuptake, and antagonistically binding to glutamatergic NMDA receptor.

3.7 DBS, OR DEEP BRAIN STIMULATION:

Deep brain stimulation (DBS) is a crucial intervention for individuals with advanced Parkinson's disease who do not react to medication, even though it is not a pharmaceutical treatment. To manage motor complaints, DBS entails implanting a device that sends electrical impulses to particular brain regions.
Mechanism: DBS acts on regions involved in movement regulation, such as the globus pallidus interna or subthalamic nucleus.

IV. NON-PHARMACOLOGICAL MANAGEMENT:

In order to enhance functional independence, reduce symptoms, and improve quality of life, non-pharmacological care of Parkinson's disease (PD) is essential. Non-pharmacological therapy targets a variety of components of the condition, including as motor function, mental health, social relationships, and general well-being, whereas pharmaceutical treatments primarily target the dopaminergic deficit and motor symptoms. This is a thorough rundown of non-pharmacological tactics:

4.1. Physical Therapy (PT)

Maintaining mobility, balance, and lowering the risk of falls all depend on physical therapy. Through exercises that improve walking patterns and lessen freezing of gait, it seeks to:
• Improve posture and gait.
Reducing fall risk requires addressing balance deficits.
• Increase flexibility and muscle strength.
•Use certain methods, such cueing strategies, in which patients are instructed to begin and control movement using visual or aural cues.

4.2. Occupational Therapy (OT):

The goal of occupational therapy is to enable people with Parkinson's disease to carry out everyday tasks on their own. It entails teaching patients how to carry out activities including

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

dressing, cooking, and grooming using adapted tools and methods.
• Teaching techniques for handling fine motor skills issues, such as writing by hand or buttoning clothing.
• Improving motor and cognitive coordination to perform tasks more effectively.

4.3. Speech and Language Therapy (SLT):

The communication and swallowing issues that are frequently observed in Parkinson's disease are addressed by speech and language therapy. This comprises:
• Voice training: Using exercises (like Lee Silverman Voice Treatment [LSVT]) to increase speaking clarity and volume.
•Dysphagia management: Strategies to control aspiration and swallowing issues.
• Exercises for speech clarity: To enhance articulation and lessen speech monotony.

4.4. Physical activity and exercise:

One of the best non-pharmacological treatments for Parkinson's disease is regular exercise. Among the advantages are: • Better motor function and less stiffness.
• Improved general endurance and cardiovascular health.
• Improved mood and a decrease in anxiety and depression.
• Common forms of exercise include tai chi, weight training, stretching, and cardiovascular exercises like walking and cycling.

4.5. CBT, or cognitive behavioral therapy:

Parkinson's disease is frequently associated with depression, anxiety, and cognitive deterioration. Cognitive behavioral therapy (CBT) can:
• Assist patients in using coping mechanisms to manage their symptoms of anxiety and sadness.
• Address negative ideas and habits to enhance mental wellness.
•Aid in the treatment of PD's cognitive symptoms, such as executive dysfunction.

4.6. Support for Nutrition and Diet

For Parkinson's disease management, a balanced diet is essential. Some dietary guidelines consist of:
• Protein management: Levodopa, a common Parkinson's drug, can be impeded by protein, thus some patients may need to modify when they consume protein.
• More fiber and water: To help with constipation, a frequent PD non-motor symptom.
In addition to vitamins, antioxidants: Vitamin E is one antioxidant that may help reduce oxidative stress.

V. SURGICAL MANAGEMENT:

When pharmacological treatments (such as dopamine replacement therapy) are no longer effective in controlling symptoms, surgery is a crucial area of research and clinical practice for Parkinson's disease (PD). Patients with severe motor fluctuations, dyskinesias, or other symptoms that are not effectively managed with medication and have advanced Parkinson's disease are typically candidates for surgery. Here is a broad summary of the primary types of Parkinson's disease surgery, along with reading recommendations:

5.1.Pallidotomy

Pallidotomy is a surgical treatment used to treat Parkinson's disease by deliberately destroying a section of the globus pallidus interna (GPi). The aberrant activity of the GPi, which regulates motor control, may be a contributing factor to the motor symptoms observed in Parkinson's disease.

• **Mechanism of Action**: The aberrant activity is decreased by eliminating a small portion of the GPi, which enhances motor control. For symptoms like stiffness and tremor, this can be helpful.
•Indications: Patients with severe Parkinson's disease (PD) who are not candidates for DBS or who do not react well to treatment may be candidates for pallidotomy.
•Results: Pallidotomy can significantly reduce motor symptoms, but it may also increase the chance of adverse effects like cognitive or speech issues.

5.2.Techniques for Lesioning (Thalamotomy):

Although less common, thalamotomy can be used to treat severe tremors, especially in Parkinson's disease patients who don't react to medicines. The thalamus, a region of the brain in charge of fine motor control, will be damaged during this surgery.

• **Mechanism of Action**: Motor signals are sent by the thalamus. Parkinson's disease-related tremors can be lessened with a thalamic lesion.
•Indications: Patients with incapacitating tremors that do not improve with treatment are usually

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

candidates for thalamotomy, especially when DBS or other surgical procedures are not an option.

5.3. Experimental Fetal Neural Transplantation:

In this procedure, dopamine-producing fetal cells are implanted into the striatum, the area of the brain affected by Parkinson's disease. Restoring dopamine function and enhancing motor control are the objectives.

• **Mechanism of Action**: It is thought that the transplanted cells will help the brain produce dopamine normally again, which will assist to reduce Parkinson's disease symptoms.
•Indications: This is not a first-line treatment for Parkinson's disease and is usually regarded as an experimental method. Only those patients who are good candidates for clinical trials are eligible.
•Outcomes: Research on the effects of fetal transplantation has been conflicting; some studies have found no benefit, while others have seen improvements in symptoms.

5.4. Gene Therapy (Experimental):

The goal of gene therapy for Parkinson's disease is to introduce genes that can enhance motor control by regulating other parts of the brain or producing more dopamine.
• Mechanism of Action: One strategy is to introduce genes that code for dopamine-producing enzymes or to produce substances that can prevent the degeneration of dopamine-producing cells.
•Indications: Gene therapy is typically a component of clinical trials and is still in the experimental stage.
•Results: Although early-stage research has yielded encouraging outcomes, gene therapy is not yet commonly applied in clinical settings.

VI. DIETARY MODIFICATIONS:

1.High Fibre Diet: Why it matters: Because PD patients have decreased gastrointestinal motility, constipation is a common problem that can make symptoms worse. Constipation can be reduced and gut health can be enhanced with a high-fiber diet.
Consume fruits, vegetables, whole grains, legumes, and seeds.
2.Adequate Protein Intake: Why it matters: Protein can affect how well levodopa, a crucial drug for Parkinson's disease, is absorbed. To maximize the effectiveness of levodopa, it is frequently recommended to minimize protein intake during the day, particularly near the time of treatment.
What to eat: To improve the absorption of medication earlier in the day, concentrate on consuming protein mostly during the evening meal.

3.Antioxidant Rich Foods:

Why it's important: Oxidative stress is thought to play a role in the progression of PD. Antioxidants can help protect neurons from damage.
What to eat: Foods rich in antioxidants, including fruits and vegetables such as berries, spinach, kale, and nuts.

4.Vitamin D and Calcium:

Why it's important: People with PD may have an increased risk of osteoporosis due to reduced physical activity and the effects of certain medications. Adequate vitamin D and calcium intake is crucial for bone health.
What to eat: Fatty fish (like salmon), fortified dairy, egg yolks, and leafy greens for vitamin D; dairy products, fortified plant milk, and leafy greens for calcium.

7.LifestyleModifications:

Regular Exercise: Why it's important: Regular physical activity helps maintain mobility, flexibility, and balance. It also reduces the risk of falls and improves overall mood.
Recommended activities: Walking, swimming, cycling, yoga, tai chi, and strength training. Physical therapy might be beneficial to tailor a program that addresses specific needs□

8. Speech and Swallowing Therapy:

Why it's important: People with PD may develop speech or swallowing difficulties, which can affect quality of life and nutrition.
What to do: Consider working with a speech-language pathologist (SLP) to help address these issues early. Swallowing exercises and speech training can help maintain function.

VII. CONCLUSION:

Parkinson's disease (PD) is a complex, progressive neurodegenerative disorder that primarily affects motor control but also brings a range of non-motor symptoms that can significantly impact quality of life. Although there is no cure for Parkinson's disease, a combination of pharmacological treatments, surgical interventions, and non-pharmacological management strategies can help alleviate symptoms, improve mobility, and maintain functionality for individuals with PD.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

Levodopa remains the cornerstone of pharmacological treatment, with dopamine agonists, MAO-B inhibitors, COMT inhibitors, and other adjunctive therapies further enhancing symptom control.Non-pharmacological interventions, including physical therapy, occupational therapy, speech and language therapy, and regular exercise, play an essential role in improving motor function, reducing falls, enhancing cognitive abilities, and managing psychological symptoms such as depression and anxiety. These interventions, when used in tandem with medications, significantly improve the quality of life for patients. Surgical treatments like deep brain stimulation (DBS) offer relief for patients with advanced PD who no longer respond well to medications. Experimental therapies, such as gene therapyand fetal neural transplantation, hold promise for future breakthroughs but remain in the research phase.Lifestyle modifications, including a balanced diet, regular exercise, and careful attention to speech and swallowing issues, further contribute to better disease management and overall well-being.While the current therapeutic approach is symptom-focused, ongoing research into disease-modifying treatments, neuroprotective strategies, and potential cures is essential to offering hope for a future where Parkinson's disease is better understood and more effectively treated. With a comprehensive treatment plan tailored to the individual's specific needs, patients with Parkinson's disease can live fulfilling and active lives for many years following their diagnosis.

REFERENCES:

[1]. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. Journal of Parkinson's disease. 2018 Dec 18;8(s1): S3-8.

[2]. Kalia LV, Lang AE. Parkinson's disease. The lancet. 2015 Aug 29;386(9996):896-912.

[3]. Tanner, C. M., & Goldman, S. M. (1996). Environmental factors and Parkinson's disease: A critical review.

[4]. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annual review of neuroscience. 1999 Mar;22(1):123-44.

[5]. Lotharius, J., Brundin, P. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein. Nat Rev Neurosci 3, 932–942 (2002).

[6]. Stamelou M, Lai SC, Aggarwal A, Schneider SA, Houlden H, Yeh TH, Batla A, Lu CS, Bhatt M, Bhatia KP. Dystonic opisthotonus: a "red flag" for neurodegeneration with brain iron accumulation syndromes?. Movement Disorders. 2013 Sep;28(10):1325-9.

[7]. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of neurology, neurosurgery & psychiatry. 2008 Apr 1;79(4):368-76.

[8]. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Current clinical pharmacology. 2007 Sep 1;2(3):234-43.

[9]. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New England Journal of Medicine. 2000 May 18;342(20):1484-91.

[10]. Kvernmo T, Houben J, Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Current topics in medicinal chemistry. 2008 Aug 1;8(12):1049-67.

[11]. Singh N, Pillay V, Choonara YE. Advances in the treatment of Parkinson's disease. Progress in neurobiology. 2007 Jan 1;81(1):29-44.

[12]. Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007 Dec;27(12P2):174S-85S.

[13]. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS drugs. 2005 Feb;19:165-84.

[14]. Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in the Management of Parkinson's Disease. CNS drugs. 2022 Mar;36(3):261-82.

[15]. Benazzi F. Bipolar II disorder: epidemiology, diagnosis and management. CNS drugs. 2007 Sep;21(9):727-40.

[16]. Dong J, Cui Y, Li S, Le W. Current pharmaceutical treatments and alternative therapies of Parkinson's disease. Current

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1150-1157 www.ijprajournal.com ISSN: 2456-4494

neuropharmacology. 2016 May 1;14(4):339-55.

[17]. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schäfer H, Bötzel K, Daniels C, Deutschländer A, Dillmann U, Eisner W, Gruber D. A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine. 2006 Aug 31;355(9):896-908.

[18]. Keus S, Munneke M, Graziano M, Paltamaa J, Pelosin E, Domingos J, Brühlmann S, Ramaswamy B, Prins J, Struiksma C, Rochester L. European physiotherapy guideline for Parkinson's disease. The Netherlands: KNGF/ParkinsonNet. 2014 Dec;191:1-53.

[19]. Nouvel F. The role of occupational therapy in Parkinson's disease. Soins; la Revue de Reference Infirmiere. 2024 Feb 16;69(883):33-6.

[20]. Won C, Jang W, Park S. Effectiveness of Lee Silverman Voice Treatment (LSVT)-BIG for Neurological Diseases Other Than Parkinson's Disease: Mini Review.

[21]. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: A systematic review and meta-analysis. Movement disorders. 2008 Apr 15;23(5):631-40.

[22]. Carey G, Lopes R, Moonen AJ, Mulders AE, de Jong JJ, Kuchcinski G, Defebvre L, Kuijf ML, Dujardin K, Leentjens AF. Cognitive behavioral therapy for anxiety in Parkinson's disease induces functional brain changes. Journal of Parkinson's Disease. 2023 Jan 31;13(1):93-103.

[23]. Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson's disease progression. Oxidative medicine and cellular longevity. 2017;2017(1):6405278.

[24]. Laitinen LV. Pallidotomy for Parkinson's disease. Neurosurgery Clinics of North America. 1995 Jan 1;6(1):105-12.

[25]. Sperling SA, Shah BB, Barrett MJ, Bond AE, Huss DS, Gonzalez Mejia JA, Elias WJ. Focused ultrasound thalamotomy in Parkinson disease: nonmotor outcomes and quality of life. Neurology. 2018 Oct 2;91(14):e1275-84.

[26]. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine. 2001 Mar 8;344(10):710-9.

[27]. Kaplitt, M. G., et al. (2007). "Safety and tolerability of gene therapy with an adeno-associated viral vector encoding glutamic acid decarboxylase for advanced Parkinson's disease." Lancet, 369(9579), 2097-2105.

[28]. Olanow, C. W., & Koller, W. C. (1998). "Medical management of Parkinson's disease." Neurology, 50(2 Suppl 1), S1-S5

[29]. Schapira, A. H., & Dexter, D. T. (2000). "The role of antioxidants in neurodegenerative diseases." Neurodegeneration, 9(4), 161-168.

[30]. Sadeghi, N., et al. (2015). "The role of vitamin D in Parkinson's disease: A review." Journal of Clinical Neuroscience, 22(6), 1077-1081.